Gil Yosipovitch, MD

An expert discusses how the evolving CSU treatment landscape includes H1 antihistamines as first-line therapy, omalizumab as second-line, and emerging treatments like dupilumab, remibrutinib, and barzolvolimab that target different mechanisms including mast cell depletion.

An expert discusses how chronic spontaneous urticaria is a recurrent inflammatory skin condition causing itchy wheals and angioedema that significantly impacts patients' quality of life, sleep, and emotional well-being.

An expert discusses how prurigo nodularis represents one of the most severe itching conditions in dermatology, significantly impacting patients' quality of life and sleep, and explains the importance of breaking the itch-scratch cycle while highlighting recent treatment advances with targeted biologics like dupilumab and nemolizumab.

At the 2025 Revolutionizing Atopic Dermatitis Conference, Gil Yosipovitch, MD, explored the pathophysiology of chronic itch through the lens of type 2 cytokine inhibition, neuromodulatory therapies, and more.

Gil Yosipovitch, MD, reviews differences including lesion appearance, cytokine pathways, treatment options, and more.

Gil Yosipovitch, MD, addresses the severity of chronic itch and sleep disturbances in patients with atopic dermatitis.

Gil Yosipovitch, MD, discusses the correlation between increased BNP levels and chronic pruritus of unknown origin.

Step therapy policies place a large administrative burden on physicians, which, in turn, takes time away from patient care. Some states are working on legislation that seeks to regulate step therapy protocols and ensure they are safe for patients.